New CEO – Carlos de Sousa

  • 08:37

Immunicum today announced the appointment of Carlos de Sousa as Immunicum’s Chief Executive Officer effective on October 1, 2016…. Read more

Company presentation

  • 17:23

Immunicum’s CEO, Jamal El-Mosleh, holds a company presentation at Redeye Fight Cancer 2016. See the presentation here: Company… Read more

Redeye Immunicum analysis

  • 17:20

Redeye updates the company analysis of Immunicum. Read it here in Swedish: Analysis.

SITC poster presentation

  • 10:47

Society for Immunotherapy of Cancer (SITC) has accepted Immunicum’s poster containing clinical data from INTUVAX – HCC I/II… Read more

RCC I/II improved survival data

  • 10:54

Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients Immunicum initiated a phase… Read more

CD70 patent in the US

  • 14:07

Immunicum today announced that the United States Patent and Trademark Office (USPTO) intends to grant a patent relating to… Read more

CD70 patent in China

  • 09:03

Immunicum announces that a patent application in China regarding the Company’s CD70-technology will be granted. Press release 160726… Read more

IND application

  • 15:31

Immunicum today announced that the Company has submitted an Investigational New Drug (IND) application to the Food and Drug… Read more

Chief Medical Officer

  • 12:24

Immunicum announced today that Peter Suenaert, M.D., Ph.D., has accepted the offer to take the role as the Company’s… Read more

Preliminary melanoma plans

  • 09:35

Immunicum announced preliminary plans to conduct two separate studies with INTUVAX for the treatment of advanced melanoma in… Read more